Health Care Resource Utilization and Costs Among Adults with Atopic Dermatitis in the United States: A Claims-Based Analysis

Drucker, Aaron M.; Qureshi, Abrar A.; Amand, Caroline; Villeneuve, Sara; Gadkari, Abhijit; Chao, Jingdong; Kuznik, Andreas; Bégo-Le-Bagousse, Gaëlle; Eckert, Laurent

doi:10.1016/j.jaip.2017.10.024

Cited by 49 publications

(49 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results were in line with a US-based study of ADrelated HCRU, with severity defined on clinical variables. 49 A previous comparison of HCRU in patients with AD based on the US NHWS did not find any significant difference between those with self-reported moderate-to-severe versus mild disease, but small numbers of patients reporting the higher level of disease severity might have limited the power of the analysis. 29 Regional differences in health care systems and clinical practice are another possible contributor to the differences in study findings.…”

Section: Discussionmentioning

confidence: 84%

Burden of illness in adults with atopic dermatitis: Analysis of National Health and Wellness Survey data from France, Germany, Italy, Spain, and the United Kingdom

Eckert

Gupta

Gadkari

et al. 2019

Journal of the American Academy of Dermatology

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 84%

Burden of illness in adults with atopic dermatitis: Analysis of National Health and Wellness Survey data from France, Germany, Italy, Spain, and the United Kingdom

Eckert

Gupta

Gadkari

et al. 2019

Journal of the American Academy of Dermatology

Self Cite

View full text Add to dashboard Cite

show abstract

“…As the management of AD has evolved since the introduction of dupilumab, the primary goal of this study was to evaluate the current real-world treatment patterns for patients with moderate-to-severe AD, including the distribution of advanced treatments used, adherence to and persistence with those treatments, and the frequency of combination therapy in a cohort of US commercially insured patients with AD. Recent studies showed that annual costs for patients with AD in commercial health plans who were treated with either phototherapy or systemic treatments (i.e., patients with ''more severe AD'') were approximately $15,000 [11,12]. However, these studies were conducted using data periods prior to the availability of dupilumab.…”

Section: Introductionmentioning

confidence: 99%

Costs and Treatment Patterns Among Patients with Atopic Dermatitis Using Advanced Therapies in the United States: Analysis of a Retrospective Claims Database

Eichenfield

DiBonaventura

Xenakis

et al. 2020

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Introduction: For many, atopic dermatitis (AD) is not adequately controlled with topical regimens. This analysis examined treatment using advanced therapies and associated costs. Methods: The IQVIA Health Plan Claims data set was analyzed. Patients aged C 12 years with AD who newly initiated advanced therapy after the availability of dupilumab (March 28, 2017) and had C 6 months continuous enrollment before and after their first advanced therapy claim (index date) were included. Advanced therapies included dupilumab, systemic corticosteroids (SCSs), systemic immunosuppressants (SISs), and phototherapy. A multivariate regression model was used to predict annualized follow-up healthcare costs. Results: In total, 1980 patients were included (61.1% female; mean age, 41.2 years [SD, 17.4]; 11.3% \ 18 years). Pre-index date, 65.2% of patients used topical corticosteroids (TCSs; 40.7% and 32.1% used medium and high potency, respectively). The most common advanced therapy was SCSs (N = 1453 [73.4%]; 69.2% prednisone) followed by dupilumab (N = 265 [13.4%]), SISs (N = 99 [5.0%]; 47.5% methotrexate), and phototherapy (N = 163 [8.2%]). Of patients treated with dupilumab, SISs, and phototherapy, 17.4%, 26.3%, and 14.1%, respectively, were prescribed SCSs postindex date. Overall, 62.6% of patients initiating SCSs, 49.1% initiating dupilumab, 64.6% initiating SISs, and 36.2% initiating phototherapy were prescribed TCSs post-index date. Mean

show abstract

“…AD has a significant effect on the quality of life (QoL) of patients and their families due to intense pruritus and resulting sleep loss and concentration problems, and its psychosocial impact (3,4). In addition to the psychosocial burden, AD also has a substantial economic burden caused by costs directly related to treatment (direct costs) including inpatient and outpatient visits, diagnostic tests, transportation costs and medication costs (5). Indirect costs, caused by productivity losses also substantially contribute to the economic burden (4).…”

mentioning

confidence: 99%

“…Several studies have attempted to quantify the economic burden of AD. However, studies are often difficult to compare as they have focused on variable costs in specific patient populations and used different definitions of direct and indirect costs (4)(5)(6)(7)(8)(9)(10). In addition, studies were performed in various healthcare systems across different countries and costs were based on claims or patient-reported data leading to a high risk of recall bias.…”

mentioning

confidence: 99%

Economic Burden of Adult Patients with Moderate to Severe Atopic Dermatitis Indicated for Systemic Treatment

Ariëns¹,

Nimwegen²,

Shams³

et al. 2019

Acta Derm Venerol

View full text Add to dashboard Cite

Given the introduction of new therapies targeting specific immune pathways for atopic dermatitis, information on the economic burden of patients with atopic dermatitis is needed. In 90 adult patients with atopic dermatitis indicated for systemic treatment, direct costs (including medication use and healthcare resource utilization) and costs due to reduced work productivity were calculated. Total costs (including directs and costs of productivity loss) were €15,231 per patient per year for the total group and €20,695 for patients with uncontrolled disease vs. €11,287 for patients with controlled disease. Costs of productivity loss had the larger impact on total costs. These data indicate that patients with atopic dermatitis using systemic immunosuppressive treatment incur considerable direct costs and costs of productivity loss. Given the introduction of new therapies targeting specific immune pathways for atopic dermatitis (AD), information on the economic burden of AD patients is needed. Direct costs (medication use and healthcare resource utilization) and costs of productivity loss were studied in 90 adult patients with AD indicated for systemic treatment. Costs were calculated for patients with controlled (Investigator Global Assessment (IGA) 0-2) and uncontrolled (IGA 3-5) disease at inclusion. Mean (95% confidence interval (95% CI)) total direct costs were €5,191 (€4,382-6,019) per patient per year (PPY), €4,401 (€3,695-5,215) for patients with controlled AD vs. €6,993 (€5,552-8,406), mean difference €2,593 (€820-4,282) (p=0.014) for patients with uncontrolled AD. Costs of productivity loss were €10,040 (€6,260-14,012) PPY for the total group, €6,886 (€4,188-10,129) PPY for patients with controlled AD vs. €13,702 (€6,124-22,996) for patients with uncontrolled AD, mean difference €6,816 (-€1,638-16,677; p=0.148). Total costs (direct costs+costs of productivity loss) were €15,231 (€11,487-19,455) PPY for the total group, €11,287 (€7,974-15,436) for patients with controlled AD vs. €20,695 (€14,068-34,564), mean difference €9,408 (-€119-19,964) (p=0.077) for patients with uncontrolled AD. Patients with AD using systemic immunosuppressive treatment incur considerable direct costs and costs of productivity loss.

show abstract

Health Care Resource Utilization and Costs Among Adults with Atopic Dermatitis in the United States: A Claims-Based Analysis

Cited by 49 publications

References 16 publications

Burden of illness in adults with atopic dermatitis: Analysis of National Health and Wellness Survey data from France, Germany, Italy, Spain, and the United Kingdom

Burden of illness in adults with atopic dermatitis: Analysis of National Health and Wellness Survey data from France, Germany, Italy, Spain, and the United Kingdom

Costs and Treatment Patterns Among Patients with Atopic Dermatitis Using Advanced Therapies in the United States: Analysis of a Retrospective Claims Database

Economic Burden of Adult Patients with Moderate to Severe Atopic Dermatitis Indicated for Systemic Treatment

Contact Info

Product

Resources

About